EUVIMEDEUVIMED entdecken
Querschnittstudie

Injury labels and patient-problem codes in FDA adverse event reports for robotic arthroplasty platforms: a cross-sectional analysis of 12,175 MAUDE reports

Mohammed H Abushal

Journal of Robotic Surgery · 07.11.2026 · 20 (1)

DOI: 10.1007/s11701-026-04162-2 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift Journal of Robotic Surgery, online erschienen am 07.11.2026. Verfasst von Mohammed H Abushal. Beteiligte Einrichtung: Department of Surgery, Faculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia. Mabushal@ut.edu.sa. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Robotic Surgical Procedures, Arthroplasty, Product Surveillance, Postmarketing. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

US Food and Drug Administration (FDA) device reports carry two structured fields used to describe patient harm: the event-type label and patient-problem codes. I quantified how often prespecified contrasting categories of these fields co-occur in reports for robotic arthroplasty platforms. Cross-sectional analysis of reports in the Manufacturer and User Facility Device Experience (MAUDE) database, accessed through openFDA (product code OLO, received to 30 September 2026) matching search definitions for Mako and NAVIO/CORI (manufacturer field) and VELYS and ROSA Knee/Recon (brand field); procedures were not confirmed. The primary outcome was co-occurrence of an injury label with a no-consequence code, or of a non-injury label with a harm-related code, counted exactly from archived report-level records. Sensitivity analyses included harmonised definitions and duplicate screening. Of 12,175 reports, 2,106 (17.3%) were labelled injury, from 0.6% (VELYS) to 44.2% (ROSA). A no-consequence code appeared in 46.0% (Mako), 71.3% (NAVIO/CORI) and 59.5% (ROSA) of injury-labelled reports; a harm-related code appeared in 12.8% of non-injury VELYS reports. Overall, 1,785 reports (14.7%; 95% confidence interval 14.0-15.3) showed co-occurrence. The injury-label share exceeded the harm-related code share for Mako, NAVIO/CORI and ROSA; for VELYS, the reverse held. These directions persisted with clinical code categories, harmonised definitions and duplicate removal. Contrasting label and patient-code categories frequently co-occurred, in platform-specific directions. This reflects the fields' different purposes, not demonstrated coding disagreement, patient harm or device safety. Because reporting practices and search-field composition may contribute, harm proportions from either field alone should not be used to rank platforms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

United States Food and Drug AdministrationRobotic Surgical ProceduresArthroplastyProduct Surveillance, PostmarketingProduct LabelingUnited StatesCross-Sectional StudiesHumansDatabases, Factual

Stichwörter der Autor:innen

Adverse eventsMAUDEMedical device reportingPatient-problem codesPostmarket surveillanceRobotic arthroplasty

Autor:innen und Institutionen

  • Department of Surgery, Faculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia. Mabushal@ut.edu.sa.

Zitieren

APA

Abushal, M. H. (2026). Injury labels and patient-problem codes in FDA adverse event reports for robotic arthroplasty platforms: a cross-sectional analysis of 12,175 MAUDE reports. Journal of Robotic Surgery, 20(1). https://doi.org/10.1007/s11701-026-04162-2

Vancouver

Abushal MH. Injury labels and patient-problem codes in FDA adverse event reports for robotic arthroplasty platforms: a cross-sectional analysis of 12,175 MAUDE reports. Journal of Robotic Surgery. 2026;20(1). doi:10.1007/s11701-026-04162-2

BibTeX
@article{Abushal2026,
  author = {Abushal, Mohammed H},
  title = {Injury labels and patient-problem codes in FDA adverse event reports for robotic arthroplasty platforms: a cross-sectional analysis of 12,175 MAUDE reports},
  journal = {Journal of Robotic Surgery},
  year = {2026},
  volume = {20},
  number = {1},
  doi = {10.1007/s11701-026-04162-2}
}
Kostenlos starten →